Mundipharma secures rights to VivaGel BV line
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Mundipharma is poised to expand its consumer healthcare portfolio, after it snapped up the rights to Starpharma’s VivaGel BV bacterial vaginosis treatment in a number of regions, including Asia.